420 related articles for article (PubMed ID: 23150894)
1. The social and economic burden of stroke survivors in Italy: a prospective, incidence-based, multi-centre cost of illness study.
Fattore G; Torbica A; Susi A; Giovanni A; Benelli G; Gozzo M; Toso V
BMC Neurol; 2012 Nov; 12():137. PubMed ID: 23150894
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of patients admitted to stroke units in Spain.
Alvarez-Sabín J; Quintana M; Masjuan J; Oliva-Moreno J; Mar J; Gonzalez-Rojas N; Becerra V; Torres C; Yebenes M;
Eur J Health Econ; 2017 May; 18(4):449-458. PubMed ID: 27084749
[TBL] [Abstract][Full Text] [Related]
3. Social and economic costs and health-related quality of life in stroke survivors in the Canary Islands, Spain.
Lopez-Bastida J; Oliva Moreno J; Worbes Cerezo M; Perestelo Perez L; Serrano-Aguilar P; Montón-Álvarez F
BMC Health Serv Res; 2012 Sep; 12():315. PubMed ID: 22970797
[TBL] [Abstract][Full Text] [Related]
4. Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.
Cruess AF; Zlateva G; Xu X; Soubrane G; Pauleikhoff D; Lotery A; Mones J; Buggage R; Schaefer C; Knight T; Goss TF
Pharmacoeconomics; 2008; 26(1):57-73. PubMed ID: 18088159
[TBL] [Abstract][Full Text] [Related]
5. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
6. Social/economic costs and health-related quality of life in patients with scleroderma in Europe.
López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Péntek M; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():109-17. PubMed ID: 27038626
[TBL] [Abstract][Full Text] [Related]
7. [Direct and indirect costs associated with respiratory allergic diseases in Italy. A probabilistic cost of illness study].
Marcellusi A; Viti R; Incorvaia C; Mennini FS
Recenti Prog Med; 2015 Oct; 106(10):517-27. PubMed ID: 26442978
[TBL] [Abstract][Full Text] [Related]
8. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
[TBL] [Abstract][Full Text] [Related]
9. Social/economic costs and health-related quality of life in patients with Prader-Willi syndrome in Europe.
López-Bastida J; Linertová R; Oliva-Moreno J; Posada-de-la-Paz M; Serrano-Aguilar P; Kanavos P; Taruscio D; Schieppati A; Iskrov G; Baji P; Delgado C; von der Schulenburg JM; Persson U; Chevreul K; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():99-108. PubMed ID: 27038627
[TBL] [Abstract][Full Text] [Related]
10. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
[TBL] [Abstract][Full Text] [Related]
11. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation.
Gerzeli S; Tarricone R; Zolo P; Colangelo I; Busca MR; Gandolfo C
Neurol Sci; 2005 Jun; 26(2):72-80. PubMed ID: 15995823
[TBL] [Abstract][Full Text] [Related]
12. Return to work after specialised burn care: A two-year prospective follow-up study of the prevalence, predictors and related costs.
Goei H; Hop MJ; van der Vlies CH; Nieuwenhuis MK; Polinder S; Middelkoop E; van Baar ME;
Injury; 2016 Sep; 47(9):1975-82. PubMed ID: 27085837
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.
Chuvarayan Y; Finger RP; Köberlein-Neu J
Eur J Health Econ; 2020 Feb; 21(1):115-127. PubMed ID: 31493181
[TBL] [Abstract][Full Text] [Related]
14. Social/economic costs and health-related quality of life in patients with histiocytosis in Europe.
Iskrov G; Astigarraga I; Stefanov R; López-Bastida J; Linertová R; Oliva-Moreno J; Serrano-Aguilar P; Posada-de-la-Paz M; Schieppati A; Taruscio D; Péntek M; von der Schulenburg JM; Kanavos P; Chevreul K; Persson U; Fattore G;
Eur J Health Econ; 2016 Apr; 17 Suppl 1():67-78. PubMed ID: 27042831
[TBL] [Abstract][Full Text] [Related]
15. Medical resource use and costs of health care after acute stroke in Germany.
Rossnagel K; Nolte CH; Muller-Nordhorn J; Jungehulsing GJ; Selim D; Bruggenjurgen B; Villringer A; Willich SN
Eur J Neurol; 2005 Nov; 12(11):862-8. PubMed ID: 16241975
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of diverticular disease: An observational analysis based on real world data from an Italian region.
Mennini FS; Sciattella P; Marcellusi A; Toraldo B; Koch M
Dig Liver Dis; 2017 Sep; 49(9):1003-1008. PubMed ID: 28663067
[TBL] [Abstract][Full Text] [Related]
17. The burden of COPD in Italy: results from the Confronting COPD survey.
Dal Negro R; Rossi A; Cerveri I
Respir Med; 2003 Mar; 97 Suppl C():S43-50. PubMed ID: 12647942
[TBL] [Abstract][Full Text] [Related]
18. Health related quality of life, service utilization and costs for patients with Huntington's disease in Norway.
van Walsem MR; Frich JC; Gómez Castañeda M; Howe EI; Pihlstrøm L; Andelic N; Aas E
BMC Health Serv Res; 2022 Dec; 22(1):1527. PubMed ID: 36517848
[TBL] [Abstract][Full Text] [Related]
19. Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011.
Mangen MJ; Bouwknegt M; Friesema IH; Haagsma JA; Kortbeek LM; Tariq L; Wilson M; van Pelt W; Havelaar AH
Int J Food Microbiol; 2015 Mar; 196():84-93. PubMed ID: 25528537
[TBL] [Abstract][Full Text] [Related]
20. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
